Adverum Biotechnologies Inc (NAS:ADVM)
$ 8.75 -0.18 (-2.02%) Market Cap: 181.62 Mil Enterprise Value: 163.87 Mil PE Ratio: 0 PB Ratio: 1.00 GF Score: 50/100

Q2 2020 Adverum Biotechnologies Inc Earnings Call Transcript

Aug 10, 2020 / 08:30PM GMT
Release Date Price: $187 (+1.30%)
Operator

Thank you for standing by. This is the conference operator. Welcome to the Adverum Biotechnologies conference call. (Operator Instructions)

I would now like to turn the conference over to Myesha Lacy of Investor Relations and Corporate Communications. Please go ahead.

Myesha Lacy
Adverum Biotechnologies, Inc. - VP of IR & Corporate Communications

Thank you, operator, and welcome, everyone. Today, we issued a press release to share new data from our OPTIC Phase I clinical trial of ADVM-022, report our financial results for the second quarter of 2020 and provide a business update. A copy of this release is available on the Press Releases page of the Investor Relations section of our corporate website at www.adverum.com. Please note that a replay of today's call and a copy of today's slide presentation will be available on the Events and Presentations section of the IR portion of our website.

Joining me today is Dr. Laurent Fischer, Chief Executive Officer; Leone Patterson,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot